Patrick Gallagher
Corporate Officer/Principal presso SENSEI BIOTHERAPEUTICS, INC.
Patrimonio netto: 34 130 $ in data 30/04/2024
Profilo
Patrick Gallagher is currently the Chief Business Officer at Sensei Biotherapeutics, Inc. He previously worked as the Senior Director of Business Development at Radius Health, Inc. from 2016 to 2018.
From 2020 to 2022, he served as the Managing Director at Binney Street Partners, LLC.
Patrick also held positions at Pfizer Inc. as the Head of Sales & Marketing, AMAG Pharmaceuticals, Inc. as the Head of Business Development, and Celexion LLC as the Manager of Business Development.
Additionally, he worked as a Principal at Aquilo Partners LP from 2018 to 2020.
Patrick obtained a graduate degree in Masters of Business Administration from Boston University and an undergraduate degree from Ohio Wesleyan University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
15/02/2023 | 34 130 ( 0.14% ) | 34 130 $ | 30/04/2024 |
Posizioni attive di Patrick Gallagher
Società | Posizione | Inizio |
---|---|---|
SENSEI BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2022 |
Precedenti posizioni note di Patrick Gallagher
Società | Posizione | Fine |
---|---|---|
Binney Street Partners, LLC | Corporate Officer/Principal | 01/06/2022 |
Aquilo Partners LP
Aquilo Partners LP Investment ManagersFinance Aquilo Partners LP provides corporate finance, mergers & acquisitions and strategic advisory services to public and private life science companies. It also provides buyside M&A, sellside M&A, partnering and private placement. The company was founded by Brian Polzak, John Rumsey and James Zanze in 2001 and is located in San Francisco, CA. | Corporate Officer/Principal | 01/01/2020 |
RADIUS HEALTH, INC. | Corporate Officer/Principal | 01/01/2018 |
PFIZER, INC. | Vendite & Marketing | - |
AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Patrick Gallagher
Boston University | Graduate Degree |
Ohio Wesleyan University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
PFIZER, INC. | Health Technology |
Aziende private | 6 |
---|---|
Celexion LLC
Celexion LLC Pharmaceuticals: MajorHealth Technology Celexion LLC develops platform technologies and products in the pharmaceutical, industrial, agricultural and life science research sectors. The company was founded by Brian Baynes in 2009 and is headquartered in Cambridge, MA. | Health Technology |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Sensei Biotherapeutics, Inc. | |
Binney Street Partners, LLC | |
Aquilo Partners LP
Aquilo Partners LP Investment ManagersFinance Aquilo Partners LP provides corporate finance, mergers & acquisitions and strategic advisory services to public and private life science companies. It also provides buyside M&A, sellside M&A, partnering and private placement. The company was founded by Brian Polzak, John Rumsey and James Zanze in 2001 and is located in San Francisco, CA. | Finance |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Patrick Gallagher